Aptevo Therapeutics Inc

APVONASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.60 USD
↗ 0.26 (11.11%)AT CLOSE (11:59 AM EDT)
2.23
↘ 0.37 (14.23%)
POST MARKET (AS OF 06:37 PM EDT)
Post Market
AS OF 06:37 PM EDT
2.23
↘ 0.37 (14.23%)
🟢Market: OPEN

Aptevo Therapeutics Inc (APVO) is currently trading at $2.23. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Sep 2, 2026.

Open?$2.34
High?$2.77
Low?$2.33
Prev. Close?$2.34
Volume?1.0M
Avg. Volume?39.6K
VWAP?$2.54
Rel. Volume?25.65x
Bid / Ask
Bid?$2.25 × 100
Ask?$2.99 × 100
Spread?$0.74
Midpoint?$2.62
Valuation & Ratios
Market Cap?4.2M
Shares Out?1.8M
Float?1.2M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?0.70
EPS?-$15.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
33
Market Cap
4.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aptevotherapeutics.com
Listed
2016-07-20
Address
2401 4TH AVE.
SEATTLE, WA 98121
Phone: 206-838-0500
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-33.14Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?6.92%Elevated
Short Interest?81.7K
Days to Cover?2.4
Free Float1.2M
Avg Daily Volume33.7K
Settlement Date2026-08-14
Financial Health
Current Ratio?2.08Strong
Quick Ratio?2.08Strong
Cash Ratio?1.89Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.70CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-463.2%WEAK▾
ROA?
S&P
3
-192.7%WEAK▾
Cash Flow & Enterprise
FCF?$-25343000
Enterprise Value?$-5561097
Fundamentals ratios updated end of day
MarketsMoversWatchlist